Overview Thromboprophylaxis in Oesophageal Cancer Patients Status: Recruiting Trial end date: 2024-05-01 Target enrollment: Participant gender: Summary The purpose of the study is to examine the efficacy and safety of prolonged thromboprophylactic treatment with Fragmin® in oesophageal cancer patients undergoing intended curative surgery. Phase: Phase 4 Details Lead Sponsor: University of AarhusCollaborator: Aarhus University HospitalTreatments: DalteparinHeparinHeparin, Low-Molecular-WeightTinzaparin